GUANGZHOU, China, June 3 China Medicine Corporation(OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), primarily amanufacturer, leading distributor and developer of Western pharmaceuticals,traditional Chinese medicines ("TCM"), and other nutraceuticals, todayannounced the results of its Annual Meeting of Stockholders (the "AnnualMeeting") held on May 27, 2010.
At the Annual Meeting, stockholders elected each of the following nomineesto the board of directors of the Company to serve until the next annualmeeting of stockholders: Mr. Senshan Yang, Ms. Minhua Liu, Dr. Rachel Gong, Mr.Ryan Shih, Mr. Daniel Shih, Mr. Sean Shao and Mr. Ian Robinson.
"Our shareholders have approved a seasoned group of professionals to serveon our board of directors. We believe our board members will be invaluable toChina Medicine as we execute our business plan and continue our evolution as apublic company," commented Mr. Senshan Yang, Chairman and CEO of ChinaMedicine Corporation.
For additional information, please refer to the Form 8-K filed with theSecurities and Exchange Commission on June 2, 2010.
About China Medicine Corporation
China Medicine Corporation, a comprehensive enterprise with a research anddevelopment centre, manufacturing facilities and well established salesnetwork, engages in the production and distribution of prescription and overthe counter ("OTC") drugs, traditional Chinese medicine products, herbs anddietary-supplements, medical devices, and medical formulations in China. TheCompany distributes its products to wholesale distributors, including morethan 300 hospitals and 500 medicine companies that sell to over 2,000 drugstores in 28 provinces throughout China. The Company is developing a number ofproprietary products for a variety of uses, including oncology, high bloodpressure and the removal of toxins from food and animal feeds.
This press release contains forward-looking statements concerning theCompany's business and products. The Company's actual results may differmaterially depending on a number of risk factors including, but not limited to,the following: general economic and business conditions, obtaining regulatoryapproval for new products, government support for rural health care,competition from existing and new competitors, changes in technology, andvarious other factors beyond its control. All forward-looking statements areexpressly qualified in their entirety by this Cautionary Statement and therisk factors detailed in the Company's reports filed with the Securities andExchange Commission. China Medicine Corporation undertakes no duty to reviseor update any forward-looking statement to reflect events or circumstancesafter the date of this release.For more information, please contact: Company Contact: Ms. Gavin Chen Assistant to CFO China Medicine Corporation Tel: +86-20-8739-2102 Email: [email protected]
Investor Relations Contact: Ms. Lei Huang, Account Manager CCG Investor Relations Tel: +1-646-833-3417 (NY Office) Email: [email protected]
Web: http://www.ccgirasia.com Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 Email: [email protected]
SOURCE China Medicine Corporation